tiprankstipranks
Trending News
More News >
VETOQUINOL (FR:VETO)
:VETO

VETOQUINOL (VETO) AI Stock Analysis

Compare
4 Followers

Top Page

FR

VETOQUINOL

(LSE:VETO)

Rating:76Outperform
Price Target:
€82.00
▲(7.33%Upside)
VETOQUINOL's overall stock score reflects strong financial performance and a fair valuation. Solid profitability and stable balance sheet are significant strengths. Technical indicators suggest cautious sentiment, tempered by a lack of momentum signals. Improvement in cash flow growth could enhance long-term prospects.
Positive Factors
Earnings Growth
Vetoquinol's adjusted EBIT has returned to growth for the first time in 3 years, marking the start of a positive upturn.
Financial Performance
The company's high gross margin and strong financial resources are expected to accelerate EPS growth.
Negative Factors
Potential Delisting
The group has a net cash position of at least €150m, representing firepower of €450m, which may incentivize the majority shareholder to attempt to delist the company if the strong discount persists.

VETOQUINOL (VETO) vs. iShares MSCI France ETF (EWQ)

VETOQUINOL Business Overview & Revenue Model

Company DescriptionVetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, and dogs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
How the Company Makes MoneyVetoquinol generates revenue primarily through the sale of its animal health products, which are distributed to veterinarians, farmers, and pet owners. The company's key revenue streams include pharmaceuticals for disease prevention and treatment, vaccines to protect against infectious diseases, and nutraceuticals to support animal health and performance. In addition to direct sales, Vetoquinol benefits from strategic partnerships and collaborations with research institutions and other companies to enhance its product offerings and expand market reach. The company's earnings are also influenced by factors such as regulatory approvals, market demand for veterinary products, and advancements in veterinary medicine.

VETOQUINOL Financial Statement Overview

Summary
VETOQUINOL demonstrates strong profitability and efficient operations. The income statement shows robust profit margins and consistent growth, while the balance sheet reflects a stable capital structure with low leverage. Cash flows are positive, though there is room for improvement in cash flow growth.
Income Statement
82
Very Positive
VETOQUINOL shows strong financial performance in its income statement. The gross profit margin is healthy, reflecting efficient production and service delivery. There is consistent revenue growth with a notable increase in net income, signaling robust profitability. EBIT and EBITDA margins are also solid, indicating effective operational management and cost control. However, the revenue growth rate has been moderate, highlighting the need for further expansion in market reach.
Balance Sheet
78
Positive
The balance sheet of VETOQUINOL is solid, characterized by a low debt-to-equity ratio, which underscores the company's prudent financial management and low leverage risk. The return on equity is commendable, showcasing effective use of shareholders' equity to generate profits. The equity ratio is strong, demonstrating a solid capital structure. Nonetheless, a slight increase in total liabilities warrants monitoring to maintain financial stability.
Cash Flow
75
Positive
VETOQUINOL maintains a positive cash flow position, with stable operating cash flows and a healthy free cash flow to net income ratio. The operating cash flow to net income ratio indicates efficient cash generation relative to net income. However, there has been a decrease in free cash flow growth rate, which suggests a need for enhanced cash flow management to support future investments and operations.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue539.20M529.27M539.78M521.27M427.47M
Gross Profit387.45M291.38M172.37M167.37M123.98M
EBITDA114.08M112.33M103.46M116.86M59.29M
Net Income58.69M55.56M47.99M62.86M19.22M
Balance Sheet
Total Assets744.13M692.23M651.85M624.56M646.09M
Cash, Cash Equivalents and Short-Term Investments206.33M147.46M93.71M69.00M129.44M
Total Debt21.12M17.63M17.42M15.38M124.86M
Total Liabilities168.20M165.12M167.19M183.21M274.26M
Stockholders Equity575.84M527.01M484.57M441.26M371.75M
Cash Flow
Free Cash Flow68.15M70.38M39.90M56.76M-53.45M
Operating Cash Flow85.83M89.39M62.39M89.17M92.01M
Investing Cash Flow-15.65M-18.88M-21.52M-33.45M-145.14M
Financing Cash Flow-16.03M-15.50M-15.60M-120.31M102.20M

VETOQUINOL Technical Analysis

Technical Analysis Sentiment
Positive
Last Price76.40
Price Trends
50DMA
72.65
Positive
100DMA
73.56
Positive
200DMA
75.32
Positive
Market Momentum
MACD
0.63
Negative
RSI
65.65
Neutral
STOCH
81.35
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:VETO, the sentiment is Positive. The current price of 76.4 is above the 20-day moving average (MA) of 72.52, above the 50-day MA of 72.65, and above the 200-day MA of 75.32, indicating a bullish trend. The MACD of 0.63 indicates Negative momentum. The RSI at 65.65 is Neutral, neither overbought nor oversold. The STOCH value of 81.35 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:VETO.

VETOQUINOL Peers Comparison

Overall Rating
UnderperformOutperform
Sector (55)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
€903.52M15.3610.64%1.01%1.88%5.79%
55
Neutral
€4.83B18.24-49.50%1.92%13.92%-4.82%
€395.92M34.312.94%5.36%
€8.56B24.768.89%1.35%
€421.76M-44.11%
€2.83B19.5714.95%0.43%
37
Underperform
€556.88M
-1.66%-6.31%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FR:VETO
VETOQUINOL
76.40
-16.78
-18.01%
GB:0DTF
Boiron SA
22.40
-8.82
-28.25%
GB:0MH6
Ipsen
103.50
-5.12
-4.71%
GB:0OB3
Valneva
2.44
-0.75
-23.51%
GB:0NM7
Virbac SA
339.50
-9.92
-2.84%
FR:MEDCL
MedinCell SA
16.84
1.98
13.32%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 27, 2025